The comparison of fecal occult blood test screening and flexible sigmoidoscopy in reducing mortality risk in colorectal cancer patients: Systematic review and meta-analysis

Mazen; Bogi Pratomo Wibowo

doi:10.36216/jpd.v8i2.246

Authors

Mazen Internal Medicine Department, Faculty of Medicine Brawijaya University, Malang, Indonesia
Bogi Pratomo Wibowo Internal Medicine Department, Faculty of Medicine Brawijaya University, Malang, Indonesia

DOI:

https://doi.org/10.36216/jpd.v8i2.246

Keywords:

fecal occult blood test, flexible sigmoidoscopy, colorectal cancer

Abstract

Introduction: Colorectal cancer is a malignancy originating from the colon and is the second most common new case in women. Most patients come for treatment at an advanced stage so they have a low life expectancy. Screening in colorectal cancer patients is expected to be used for early detection so as to speed up the management of colorectal cancer patients. Fecal occult blood test (FOBT) and flexible sigmoidoscopy (FS) are colorectal cancer screening that has been applied. However, the effectiveness of the two is still contradictory, so a systematic review and meta-analysis is needed to evaluate their effectiveness.

Objective: To explore the use of FOBT and FS in colorectal cancer screening.

Methods: A literature search was performed on Pubmed, Google scholars, and Cocraine, CINAHL. Selection of titles and abstracts based on inclusion and exclusion criteria, double filter, journal read in full. This study obtained was assessed for its validity.

Result: There are 10 journals analyzed. The use of FS is more effective than FOBT in reducing colorectal cancer mortality. The use of FOBT has an effect on colorectal cancer mortality 0.86 (95% CI 0.79, 0.94 p = 0.001). The use of FS had a significant effect on colorectal cancer 0.82 (95% CI 0.88, 0.98 p = 0.03). Both of these screenings cannot reduce the incidence of colorectal cancer.

Conclusion: FS more effective to reducing mortality than FOBT on colorectal cancer.

Downloads

Download data is not yet available.

References

GLOBOCAN. New Global Cancer Data. 2020.

Onyoh EF, Hsu WF, Chang LC, et al. The Rise of Colorectal Cancer in Asia: Epidemiology, Screening, and Management. Curr Gastroenterol Rep. 2019;21(8):36.

Makmun D, Simadibrata M, Abdullah M, et al. Colorectal cancer patients in a tertiary hospital in Indonesia: Prevalence of the younger population and associated factors. World J Clin Cases. 2021;9(32):9804-14.

Rahadiani N, Habiburrahman M, Abdullah M, et al. Analysing 11 years of incidence trends, clinicopathological characteristics, and forecasts of colorectal cancer in young and old patients: a retrospective cross-sectional study in an Indonesian national referral hospital. BMJ Open. 2022;12(9).

Bevan R, Rutter MD. Colorectal Cancer Screening-Who, How, and When?. Clin Endosc. 2018;51(1):37-49.

Issa IA, Noureddine M. Colorectal cancer screening: An updated review of the available options. World J Gastroenterol. 2017;23(28):5086-5096.

Ramdzan AR, Abd Rahim MA, Mohamad Zaki A, et al. Diagnostic Accuracy of FOBT and Colorectal Cancer Genetic Testing: A Systematic Review & Meta-Analysis. Ann Glob Health. 2019;85(1):70.

Atkin WS, Cook CF, Cuzick J, et al. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet. 2002;359(9314):1291-1300.

Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010;375(9726):1624-1633.

Hoff G, Grotmol T, Skovlund E, et al; Norwegian Colorectal Cancer Prevention Study Group. Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. BMJ. 2009;338.

Holme Ø, Løberg M, Kalager M, et al. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial. JAMA. 2014;312(6):606-615.

Jørgensen OD, Kronborg O, Fenger C. A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut. 2002;50(1):29-32.

Schoen RE, Pinsky PF, Weissfeld JL, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med. 2012;366(25):2345-2357.

Scholefield JH, Moss SM, Mangham CM, et al. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. Gut. 2012;61(7):1036-1040.

Scholefield JH, Moss S, Sufi F, et al. Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial. Gut. 2002;50(6):840-4.

Segnan N, Armaroli P, Bonelli L, et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial--SCORE. J Natl Cancer Inst. 2011;103(17):1310-1322.

Lindholm E, Brevinge H, Haglind E. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. Br J Surg. 2008;95(8):1029-1036.

Niedermaier T, Weigl K, Hoffmeister M, et al. Flexible sigmoidoscopy in colorectal cancer screening: implications of different colonoscopy referral strategies. Eur J Epidemiol. 2018;33(5):473-484.

Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 2000;343(22):1603-1607.

Feng Y, Jin H, Guo K, et al. Causes of Death After Colorectal Cancer Diagnosis: A Population-Based Study. Front Oncol. 2021;11:647179.

Chen J, Zheng Y, Wang H, et al. Cause of death among patients with colorectal cancer: a population-based study in the United States. Aging (Albany NY). 2020;12(22):22927-22948.